M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: Targretin Gel 1%

First Posted Date: 2003-06-20

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00063076

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Hepatic Artery Infusion of CD34+ Cells

Phase 1

Withdrawn

Conditions: Stem Cell Transplantation
Liver Diseases

Interventions: Procedure: Hepatic artery infusion of CD34+ cells
Device: Cobe Spectra

First Posted Date: 2003-06-12

Last Posted Date: 2018-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00062543

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: Sulindac
Drug: Acetylsalicylic acid (Aspirin)
Other: Sulindac Placebo
Drug: Ursodiol

First Posted Date: 2003-06-06

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00062023

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: Tezacitabine (FMdC)

First Posted Date: 2003-06-02

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00061620

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2003-04-30

Last Posted Date: 2012-02-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00059605

Locations: 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Mitoxantrone (Novantrone)
Drug: Bortezomib (PS-341)

First Posted Date: 2003-04-30

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT00059631

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Phase 1

Completed

Conditions: Primary Peritoneal Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: PS-341 (Bortezomib)
Drug: Carboplatin

First Posted Date: 2003-04-30

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00059618

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: cytarabine
Drug: cyclophosphamide
Drug: methotrexate
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate

First Posted Date: 2003-04-25

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00003311

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Interaction Between Patient and Healthcare Provider: Response to Acupuncture in Knee Osteoarthritis

Not Applicable

Completed

Conditions: Osteoarthritis

Interventions: Procedure: Acupuncture
Procedure: Placebo acupuncture
Other: Usual Care

First Posted Date: 2003-04-24

Last Posted Date: 2013-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 639

Registration Number: NCT00059345

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: Filgrastim (G-CSF)
Biological: Bleomycin Sulfate (BLM)
Biological: Recombinant Interferon Alfa
Drug: Carmustine
Drug: Cytarabine (ARA-C)
Drug: Cisplatin (CDDP)
Drug: Etoposide (VP-16)
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Idarubicin
Drug: Melphalan
Drug: Leucovorin Calcium
Drug: mitoxantrone hydrochloride (DHAD)
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Methylprednisolone
Drug: Vincristine Sulfate
Radiation: Radiation Therapy

First Posted Date: 2003-04-16

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT00002835

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy